Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

753

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
SchizophreniaImpaired Cognition
Interventions
DRUG

EVP-6124

Arms 1, 2

DRUG

Placebo

Arm 3

Trial Locations (94)

Unknown

Tucson

Anaheim

Bellflower

Costa Mesa

Culver City

Downey

Escondido

Los Angeles

Oceanside

Orange

San Diego

Torrance

Lauderhill

Miami

North Miami

Orange City

Atlanta

Chicago

Wichita

Shreveport

Minneapolis

Flowood

Creve Coeur

O'Fallon

St Louis

Omaha

Marlton

Albuquerque

Cedarhurst

New York

Charlotte

Durham

Cleveland

Oklahoma City

Conshohocken

Norristown

Philadelphia

Dallas

La Plata

Caba

Córdoba

Mendoza

Melbourne

Rio de Janeiro

Itapira

São Paulo

Calgary

Penticton

Chatham

Kingston

Montreal

Achim

Berlin

Düsseldorf

Freiburg im Breisgau

Leipzig

Mittweida

München

Regebsburg

Regensburg

Stralsund

Wiesbaden

México

Guadalajara

Monterrey

Bialystok

Gdansk

Lodz

Lublin

Torun

Tuszyn

Warsaw

Talagi

Moscow

Saint Petersburg

Stavropol

Belgrade

Kragujevac

Niš

Novi Kneževac

Singapore

Barcelona

Mataró

Salamanca

Zamora

Alcorcón

Coslada

Madrid

Vigo

Donetsk

Ivano-Frankivsk

Kharkiv

Kyiv

Luhansk

All Listed Sponsors
collaborator

Syneos Health

OTHER

collaborator

NeuroCog Trials, Inc.

INDUSTRY

lead

FORUM Pharmaceuticals Inc

INDUSTRY